Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

New Investor Presentation

Primary differences from the March presentation that I noticed were as follows:

1. At page 13, in the description of efforts to explore commercializing Pro Neura for other chronic diseases, they removed the bullet point at the end of the page reading "Benign Prostate Hyperplasia, Pre-exposure prophylaxis therapy for HIV-1 prevention, Type 2 Diabetes, Attention Deficit Hyperactivity Disorder”

Unless they have stopped exploration efforts (which I doubt), there isn't any justification for the removal. Unless they have signed a nondisclosure agreement with a potential pharma partner which states they are not allowed to comment at all on the subject matter of the nondisclosure agreement.

2. At page 17, in the discussion of the ropinrole implant, a bullet point in the March presentation read "On target to file IND in Q4 2016 followed by the initial pharmacokinetic and proof of concept clinical study." In may, this has been broadened to two bullet points reading:
"Commenced non-clinical toxicology evaluation of the ropinirole implant" and "On target to file IND with the initial pharmacokinetic and proof of concept clinical study in Q4 2016."

Good news, because since March they have commenced the toxicology evaluation and appear to be committing the the Phase I proof of concept study in Q4.